Table 1 Baseline characteristics of patients, treatment, and neurohumoral measurements in the ACE genotype group
| Â | All patients | DD/ID genotype | II genotype | p* |
|---|---|---|---|---|
| Â | N = 556 | N = 393 | N = 163 | DD/ID vs. II |
Age (years) | 62.7 ± 10.5 | 62.7 ± 10.3 | 62.6 ± 10.8 | 0.972 |
Males | 74.6 | 75.1 | 73.6 | 0.722 |
Weight (kg) | 83.9 ± 14.0 | 84.2 ± 14.1 | 83.1 ± 13.9 | 0.330 |
BMI (kg/m2) | 28.1 ± 3.9 | 28.1 ± 4.0 | 27.9 ± 3.7 | 0.893 |
BP systolic (mmHg) | 135.6 ± 27.0 | 135.3 ± 27.2 | 136.1 ± 26.5 | 0.315 |
BP diastolic (mmHg) | 74.7 ± 14.4 | 74.5 ± 14.2 | 75.1 ± 15.0 | 0.302 |
Heart rate (per min) | 73.0 (52.0-108.0) | 73.0 (52.0; 107.6) | 72.0 (50.4; 109.4) | 0.941 |
Time delay (min) | 238.0 (123.0-650.0) | 245.0 (122.1; 667.0) | 228.0 (121.6; 590.2) | 0.282 |
AHF | 27.0 | 28.2 | 23.9 | 0.296 |
Mild AHF (%) | 20.3 | 22.1 | 16.0 | 0.093 |
Smokers†(%) | 54.7 | 54.7 | 54. 6 | 0.982 |
Diabetes (%) | 27.9 | 30.5 | 21.5 | 0.027 |
Hypertension (%) | 57.4 | 58.3 | 55.2 | 0.508 |
ACE inhibitors (%) | 25.4 | 24.4 | 27.6 | 0.435 |
AT II (%) | 7.0 | 7.4 | 6.1 | 0.597 |
Beta-blockers (%) | 27.2 | 27.7 | 25.8 | 0.634 |
Statins (%) | 16.5 | 16.5 | 16.6 | 0.994 |
Glucose (mmol/L) | 8.1 (5.5-17.3) | 8.2 (5.7; 17.4) | 7.7 (5.3; 16.7) | 0.006 |
Troponin I (ng/mL) | 50.2 (3.1-182.1) | 48.9 (3.2; 186.5) | 52.2 (2.4; 181.3) | 0.940 |
BNP at hospital admission (pg/mL) | 66.3 (15.0-489.7) | 66.2 (15.0; 504.1) | 68.0 (15.0; 491.0) | 0.314 |
BNP after 24 h (pg/ml) | 275.2 (68.2-890.0) | 286.7 (68.1; 892.9) | 269.3 (70.0; 1145.5) | 0.955 |
NT-ProBNP at hospital admission (pg/mL) | 223.0 (33.0-4 233.0) | 230.0 (33.0; 4512.0) | 183.0 (28.1; 5350.2) | 0.435 |
NT-ProBNP after 24 h (pg/mL) | 1946.0 (370.0-11 542.0) | 2019.0 (384.1; 10197.9) | 1805.0 (355.4; 15008.4) | 0.432 |
ACE activity (IU/L) | 30.6 (4.1-68.3) | 33.6 (4.1; 70.6) | 24.1 (4.4; 63.8) | < 0.001 |